ClinicalTrials.gg
Drug

Recaticimab clinical trials

Also written SHR-1209.

studies test it
17
open now
10
in phase 3
4
first study started
2018

How each study uses recaticimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the recaticimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Recaticimab
4

Development codes

SHR-1209
6

Studies by the year they started

17 studies that test it; most in 2025 (5)

Studies that test recaticimab, by start year
YearStudies
20181
20191
20201
20212
20221
20241
20255
20265

By phase

A phase 1/2 study counts in both.

Phase 1
4
Phase 2
5
Phase 3
4
Phase 4
5

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 7 · Other 10

Jiangsu HengRui Medicine Co., Ltd. (7) · Peking Union Medical College Hospital (3) · Hunan Cancer Hospital (1) · Peking University Cancer Hospital & Institute (1) · Second Affiliated Hospital of Nanchang University (1) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1) · Sun Yat-sen University (1) · Shanghai East Hospital (1)

Often tested with

Tested in the same studies.

Adebrelimab (3) · SHR-1701 (1) · Statins (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 3, 1 in phase 3

Studies that test recaticimab, phase 3 first.

Studies

Open first, then newest update. How each study uses recaticimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 17

Codes

What other systems call recaticimab · ClinicalTrials.gg INT014377

  • UNII (FDA) 20IE6M67UXRECATICIMABOne source FDA
  • NCI Thesaurus C175849RecaticimabOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.